The healthcare space has been hot in recent years, producing spectacular returns for some. Yet examining a few of these stocks on an Enterprise Value to Revenue or Price to Book basis could cause others to sweat, especially those holding shares in the companies on our list today.
Knight Therapeutics Inc. (TSX: GUD) – $7.40
Pharmaceuticals
Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. Its principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products in Canada and internationally. The Company has a portfolio of products in various stages of development for various geographies that include Impavido, ATryn, Photofrin, FOCUSfactor, NXN-1882 (nNOS/5HT), NXN-4622 (nNOS) and nNOS/iNOS2 Inhibitor.
- Market Cap: $765,530,925
- EV/Revenues (LTM): 386.1x
- P/B: 1.2x
- Operating Income (LTM): $25,785,720
Aurinia Pharmaceuticals Inc. (TSX: AUP) – $3.58
Biotechnology & Medical Research
Aurinia Pharmaceuticals Inc. (Aurinia) is a Canada-based, clinical stage pharmaceutical company. It is focused on the development of its therapeutic immunomodulating drug candidate, Voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. Voclosporin is used as a treatment for lupus nephritis, an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease, the requirement for life-long dialysis, or death.
- Market Cap: $117,902,157
- EV/Revenues (LTM): 268.0x
- P/B: 3.4x
- Operating Income (LTM): -$25,012,881
ProMetic Life Sciences Inc. (TSX: PLI) – $2.86
Pharmaceuticals
ProMetic Life Sciences Inc. (ProMetic) is a Canada-based biopharmaceutical company. The Company offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. The Company operates through two segments: Therapeutics and Protein Technology.
- Market Cap: $1,656,635,639
- EV/Revenues (LTM): 79.4x
- P/B: 13.4x
- Operating Income (LTM): -$47,453,000
TSO3 Inc. (TSX: TOS) – $1.54
Biotechnology & Medical Research
TSO3 Inc. encompasses the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes used in hospitals.
- Market Cap: $129,950,324
- EV/Revenues (LTM): 75.6x
- P/B: 7.8x
- Operating Income (LTM): -$6,984,760
Looking for more hidden gems? Get your free Ubika Technology 20 Monthly report.
The Ubika Technology 20 index (UT20) eased 2.7% during the past month, powering past the TSX Venture Index’s 7.9% slide yet falling short of the TSX Info. Tech Index’s gain of 2.2%. Mitel Networks Corporation (TSX: MNW) was the top-performing component company this month, jumping more than 19% after reporting better-than-expected Q3 financial results. Get your copy of the Ubika Technology 20 report here >>
Spectral Medical Inc. (TSX: EDT) – $0.78
Medical Equipment, Supplies & Distribution
Spectral Medical Inc. (Spectral), formerly Spectral Diagnostics Inc., is a therapeutic development company. Spectral is focused on the development and commercialization of a treatment for severe sepsis and septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic.
- Market Cap: $148,838,982
- EV/Revenues (LTM): 45.4x
- P/B: 14.3x
- Operating Income (LTM): -$9,214,000
Novadaq Technologies Inc. (TSX: NDQ) – $16.28
Advanced Medical Equipment & Technology
Novadaq Technologies Inc. develops and commercializes medical imaging and therapeutic devices for use in the operating room. The Company’s imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company generates revenues from the sale of medical devices and consumables, capital devices or consumable products, the rental of capital devices, royalties, upfront payments received from partners for exclusive sales and marketing rights, and extended warranty services agreements in connection with capital sales.
- Market Cap: $959,189,461
- EV/Revenues (LTM): 11.3x
- P/B: 4.8x
- Operating Income (LTM): -$49,840,986
